News and Events
Alzheimer’s Breakthrough: C₂N First to Offer a Widely Accessible Blood Test
A breakthrough in Alzheimer’s disease has arrived with C2N Diagnostics’ PrecivityAD™ blood test into the clinic. The PrecivityAD™ test is a highly sensitive Alzheimer’s blood test using mass spectrometry and is performed in a CLIA-certified lab. The PrecivityAD™ test is easy to administer, does not involve any radiation, and is non-invasive. These features are expected to make the test more accessible than other diagnostic methods that physicians use to evaluate issues with memory and thinking.
ADDF Announces Major Funding Commitment to Validate an Amyloid Blood Test for Non-Invasive Early Detection of Alzheimer’s
C₂N Diagnostics has been awarded more than $2.2 million to accelerate clinical validation and accreditation of its beta-amyloid blood test.